67 research outputs found
Data on eNOS T786 and G894T polymorphisms and peripheral blood eNOS mRNA levels in Sickle Cell Disease
No full textIn this article, we present data on endothelial Nitric Oxide Synthase (eNOS) gene T786C and G894T polymorphisms in Greek steady-state Sickle Cell Disease patients in comparison to healthy controls. Moreover, eNOS mRNA levels were determined in peripheral blood samples from 18 patients and 9 controls. This article complements our recently published article named “Prognostic value of eNOS T786C and G894T polymorphisms in Sickle Cell Disease” (I. Armenis, V. Kalotychou, R. Tzanetea, Z. Kontogeorgiou, D. Anastasopoulou, M. Mantzourani, M. Samarkos, K. Pantos, K. Konstantopoulos, I. Rombos, 2016) [1]. © 2016 The Author
Commencement Convocation Program, USF, Baccalaureates, May 5, 2017
No full textPresident\u27s Global Leadership Award - Ibrahim Gambari; Honorary Doctor of Science - Phillip Furman; Honorary Doctor of Engineering and Nursing - Patricia Flatley Brennan; Honorary Doctor of Education - Michael Gessler; King O\u27Neal Scholars - Nelly Arenas, Abdulah Barakat, Nicholas Buliga, Jheuel Carter-Guy, Harmelle Davis, Michael Gile, Daniel Gomero, Ashleigh Haliabalias, Alexis Johnson, Evan Johnson, Patrick Lepochat, Alexis Low, Jacelyn Macip Billbe, Chandler Miller, Anita Nguyen, Thao Nguyen, Lauren O\u27Farrill Blanco, Typer Palbicke, Cheyanna Patrick, Michael Putnam, Omar Rodriguez, Tracey Rose, Mary Samarkos, Shaan Sehgal, Natalie Soyster, Yonatan Tamir, Andrew Vieira, Jhulianna Vivar, and Brian Win; Outstanding Graduate - Natalie Soysterhttps://digitalcommons.usf.edu/graduation_programs/1186/thumbnail.jp
Commencement Convocation Program, USF, Baccalaureates, May 5, 2017
No full textPresident\u27s Global Leadership Award - Ibrahim Gambari; Honorary Doctor of Science - Phillip Furman; Honorary Doctor of Engineering and Nursing - Patricia Flatley Brennan; Honorary Doctor of Education - Michael Gessler; King O\u27Neal Scholars - Nelly Arenas, Abdulah Barakat, Nicholas Buliga, Jheuel Carter-Guy, Harmelle Davis, Michael Gile, Daniel Gomero, Ashleigh Haliabalias, Alexis Johnson, Evan Johnson, Patrick Lepochat, Alexis Low, Jacelyn Macip Billbe, Chandler Miller, Anita Nguyen, Thao Nguyen, Lauren O\u27Farrill Blanco, Typer Palbicke, Cheyanna Patrick, Michael Putnam, Omar Rodriguez, Tracey Rose, Mary Samarkos, Shaan Sehgal, Natalie Soyster, Yonatan Tamir, Andrew Vieira, Jhulianna Vivar, and Brian Win; Outstanding Graduate - Natalie Soysterhttps://digitalcommons.usf.edu/graduation_programs/1186/thumbnail.jp
Data on eNOS T786 and G894T polymorphisms and peripheral blood eNOS mRNA levels in Sickle Cell Disease
No full textAbstractIn this article, we present data on endothelial Nitric Oxide Synthase (eNOS) gene T786C and G894T polymorphisms in Greek steady-state Sickle Cell Disease patients in comparison to healthy controls. Moreover, eNOS mRNA levels were determined in peripheral blood samples from 18 patients and 9 controls. This article complements our recently published article named “Prognostic value of eNOS T786C and G894T polymorphisms in Sickle Cell Disease” (I. Armenis, V. Kalotychou, R. Tzanetea, Z. Kontogeorgiou, D. Anastasopoulou, M. Mantzourani, M. Samarkos, K. Pantos, K. Konstantopoulos, I. Rombos, 2016) [1]
Antimicrobial Stewardship Program (ASP) in General Hospital: An Essential Practice
No full textAntimicrobial drugs are unique among the different categories of medications as their inappropriate use has a negative impact both for the individual patient, as is the case with all other medications, and for the general population as well [...
Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model
No full textClostridioides difficile infection (CDI) remains a significant healthcare burden. Non-toxigenic C. difficile (NTCD) strains have shown a benefit in preventing porcine enteritis and in human recurrent CDI. In this study, we evaluated the efficacy of metronidazole-resistant NTCD-E4 in preventing CDI facilitated by a range of antimicrobials in an in vitro human gut model. NTCD-E4 spores (at a dose of 107) were instilled 7 days before a clinical ribotype (RT) 027 (at the same dose) strain (210). In separate experiments, four different antimicrobials were used to perturb gut microbiotas; bacterial populations and cytotoxin production were determined using viable counting and Vero cell cytotoxicity, respectively. RT027 and NTCD-E4 proliferated in the in vitro model when inoculated singly, with RT027 demonstrating high-level cytotoxin (3-5-log10-relative units) production. In experiments where the gut model was pre-inoculated with NTCD-E4, RT027 was remained quiescent and failed to produce cytotoxins. NTCD-E4 showed mutations in hsmA and a gene homologous to CD196-1331, previously linked to medium-dependent metronidazole resistance, but lacked other metronidazole resistance determinants. This study showed that RT027 was unable to elicit simulated infection in the presence of NTCD-E4 following stimulation by four different antimicrobials. These data complement animal and clinical studies in suggesting NTCD offer prophylactic potential in the management of human CDI
The philosophy of Evidence-based Medicine
No full textEvidence-based Medicine is the application of the best evidence available in the care of individual patients, using mathematical estimates of probability and risk. Although elements of EBM have appeared centuries ago, the term Evidence-based Medicine has been used for 10 years only. The spread of EBM followed studies which had shown that in contemporary medicine a significant proportion of interventions, although they are considered as the standard of care, have not proven efficacy. The two principles of EBM are that evidence alone is not enough for clinical decision making and that there is a hierarchy of evidence. Evidence-based medicine can be practiced in up to five steps i.e. formulating answerable clinical questions, searching for the best available evidence, critically appraising the evidence, applying the evidence in clinical situations and evaluating one’s effectiveness and efficiency. One does not have to go through all steps in practicing EBM, e.g. there now exist the so called secondary publications which are systematic reviews or meta-analyses of all available studies on a clinical problem or journals entirely devoted in appraisal of original studies. Notwithstanding the “success” of EBM there is a strong current of criticism on subjects practical and philosophical alike. The strongest point against EBM however is that there is no evidence that practicing EBM improves patients’ outcomes. In our opinion, EBM is a very useful instrument with wide-ranging applications in the practice of medicine. However EBM is neither a new scientific field nor a paradigm shift in contemporary medicine. As an empirical approach to clinical problems, EBM does not produce scientific knowledge and therefore it should not be given more room than it deserves, neglecting basic or clinical research. “...between man and angel there is this difference, that an angel perceives the truth by simple apprehension, whereas man becomes acquainted with a simple truth by a process from manifold data” Thomas Aquinas, Summa Theologica
- …
